• TRM$ 3.461,92 +1,37 % +$ 46,82TRM oficial (Superintendencia Financiera), vigente del 21 nov al 23 nov
  • Euro$ 3.804,64 +1,37 % +$ 51,45Referencia: TRM cruzada con la tasa del Banco Central Europeo del 20 nov; no es la cotización de mercado
  • Peso mexicano$ 181,56 +1,37 % +$ 2,45Referencia: TRM cruzada con la tasa del Banco Central Europeo del 20 nov; no es la cotización de mercado
← Volver a la comunidad
General

Why are FTC consent orders forcing CVS Caremark and Express Scripts to tear down biosimilar rebate walls?

Federal Trade Commission consent orders with CVS Caremark, Express Scripts, and OptumRx are dismantling the opaque pharmacy benefit manager profit engine, forcing healthcare conglomerates to delink administrative fees from inflated Wholesale Acquisition Cost list prices and tear down the formulary rebate walls blocking lower-cost biosimilars.

For over a decade, the Big Three PBMs—controlling nearly 80% of U.S. prescription drug claims through vertically integrated insurers Cigna, UnitedHealth Group, and CVS Health—channeled manufacturer negotiations through offshore group purchasing organizations like Ascent Health Services, Zinc, and Emisar. By tying administrative fees and rebate guarantees to a drug's Wholesale Acquisition Cost, PBMs created a perverse incentive to favor high-list-price reference biologics over interchangeable biosimilars that carried 70% lower net prices. Whenever a competing biosimilar attempted to gain preferred formulary tier placement, incumbent manufacturers threatened to withdraw bundled rebates across their entire portfolio, erecting an impenetrable rebate wall.

Under the 2026 regulatory settlements, PBMs must pass manufacturer rebates directly to patients at the point of sale, offer employer plan sponsors transparent National Average Drug Acquisition Cost (NADAC) cost-plus contracts, and stop penalizing low-WAC medications. While eliminating spread pricing—where middlemen bill employers far more than they reimburse independent pharmacies—compresses legacy PBM margins, critics argue that without structural divestiture of PBM-owned specialty pharmacies, vertically integrated insurers will simply shift profits into new administrative fees.

Will the FTC's behavioral consent orders genuinely lower out-of-pocket prescription costs and accelerate biosimilar adoption, or is breaking up vertically integrated insurer-PBMs the only real fix?

How will FTC consent orders reshape the U.S. pharmacy benefit market?

0 votos

Comentarios

Sé respetuoso. Los comentarios que reporten varias personas se ocultan hasta que los revise un moderador.

Para leer no necesitas cuenta; solo para comentar. Entras con un código que te llega al correo o con tu cuenta de Google. Mostramos solo el nombre que elijas; nunca tu correo.